The medical community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s demonstrating significant potential in clinical trials for managing obesity. Unlike some current weight loss solutions, retatrutide appears to provide a more substantial decrease in body mass and improve metabolic health, par